Cover Image
市場調查報告書

Dr. Reddy's Laboratories Limited - 產品平台分析

Dr. Reddy's Laboratories Limited - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 240919
出版日期 內容資訊 英文 39 Pages
訂單完成後即時交付
價格
Back to Top
Dr. Reddy's Laboratories Limited - 產品平台分析 Dr. Reddy's Laboratories Limited - Product Pipeline Review - 2015
出版日期: 2015年08月31日 內容資訊: 英文 39 Pages
簡介

Dr. Reddy's Laboratories Limited 是總公司設立於印度的製藥企業,從事學名藥的製劑,API的製造,生技仿製藥及品牌藥的製造。對象領域有消化器官疾病,心血管系統疾病,糖尿病,癌症,疼痛,感染疾病,兒童疾病。

本報告提供Dr. Reddy's Laboratories Limited的治療藥開發平台的現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

Dr. Reddy's Laboratories Limited 基本資料

  • Dr. Reddy's Laboratories Limited 概要
  • 主要資訊
  • 企業資料

Dr. Reddy's Laboratories Limited :R&D概要

  • 主要的治療範圍

Dr. Reddy's Laboratories Limited :開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 聯合治療模式
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式

Dr. Reddy's Laboratories Limited :開發中產品概況

  • 後期階段產品開發中產品
    • 第Ⅲ階段的產品/聯合治療模式
  • 臨床階段的開發中產品
    • 第Ⅱ階段的產品/聯合治療模式
    • 第Ⅰ階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式

Dr. Reddy's Laboratories Limited :藥物簡介

  • DFN-02
  • (gentamicin sulphate + vancomycin hydrochloride)
  • DFN-15
  • rituximab biosimilar
  • pegfilgrastim
  • bevacizumab biosimilar
  • Biosimilar 4 for Cancer
  • Biosimilar 5 for Cancer
  • darbepoetin alfa (recombinant)
  • trastuzumab biosimilar

Dr. Reddy's Laboratories Limited :開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Dr. Reddy's Laboratories Limited :開發暫停中的計劃

Dr. Reddy's Laboratories Limited :開發中止的開發中產品

  • 開發中止的開發中產品簡介

Dr. Reddy's Laboratories Limited :總公司和子公司的所在地

  • 總公司
  • 分公司及子公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07379CDB

Summary

Global Markets Direct's, 'Dr. Reddy's Laboratories Limited - Product Pipeline Review - 2015', provides an overview of the Dr. Reddy's Laboratories Limited's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Dr. Reddy's Laboratories Limited's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Dr. Reddy's Laboratories Limited including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Dr. Reddy's Laboratories Limited's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Dr. Reddy's Laboratories Limited's pipeline products

Reasons to buy

  • Evaluate Dr. Reddy's Laboratories Limited's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Dr. Reddy's Laboratories Limited in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Dr. Reddy's Laboratories Limited's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Dr. Reddy's Laboratories Limited and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Dr. Reddy's Laboratories Limited
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Dr. Reddy's Laboratories Limited and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Dr. Reddy's Laboratories Limited Snapshot
    • Dr. Reddy's Laboratories Limited Overview
    • Key Information
    • Key Facts
  • Dr. Reddy's Laboratories Limited - Research and Development Overview
    • Key Therapeutic Areas
  • Dr. Reddy's Laboratories Limited - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • Dr. Reddy's Laboratories Limited - Pipeline Products Glance
    • Dr. Reddy's Laboratories Limited - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Dr. Reddy's Laboratories Limited - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Dr. Reddy's Laboratories Limited - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Dr. Reddy's Laboratories Limited - Drug Profiles
    • DFN-02
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • (gentamicin sulphate + vancomycin hydrochloride)
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DFN-15
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • rituximab biosimilar
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • pegfilgrastim
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • bevacizumab biosimilar
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Biosimilar 4 for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Biosimilar 5 for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • darbepoetin alfa (recombinant)
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • trastuzumab biosimilar
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Dr. Reddy's Laboratories Limited - Pipeline Analysis
  • Dr. Reddy's Laboratories Limited - Pipeline Products by Target
  • Dr. Reddy's Laboratories Limited - Pipeline Products by Route of Administration
  • Dr. Reddy's Laboratories Limited - Pipeline Products by Molecule Type
  • Dr. Reddy's Laboratories Limited - Pipeline Products by Mechanism of Action
  • Dr. Reddy's Laboratories Limited - Dormant Projects
  • Dr. Reddy's Laboratories Limited - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • terbinafine
  • Dr. Reddy's Laboratories Limited - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Dr. Reddy's Laboratories Limited, Key Information
  • Dr. Reddy's Laboratories Limited, Key Facts
  • Dr. Reddy's Laboratories Limited - Pipeline by Indication, 2015
  • Dr. Reddy's Laboratories Limited - Pipeline by Stage of Development, 2015
  • Dr. Reddy's Laboratories Limited - Monotherapy Products in Pipeline, 2015
  • Dr. Reddy's Laboratories Limited - Combination Treatment Modalities in Pipeline, 2015
  • Dr. Reddy's Laboratories Limited - Partnered Products in Pipeline, 2015
  • Dr. Reddy's Laboratories Limited - Partnered Products/ Combination Treatment Modalities, 2015
  • Dr. Reddy's Laboratories Limited - Phase III, 2015
  • Dr. Reddy's Laboratories Limited - Phase II, 2015
  • Dr. Reddy's Laboratories Limited - Phase I, 2015
  • Dr. Reddy's Laboratories Limited - Preclinical, 2015
  • Dr. Reddy's Laboratories Limited - Pipeline by Target, 2015
  • Dr. Reddy's Laboratories Limited - Pipeline by Route of Administration, 2015
  • Dr. Reddy's Laboratories Limited - Pipeline by Molecule Type, 2015
  • Dr. Reddy's Laboratories Limited - Pipeline Products by Mechanism of Action, 2015
  • Dr. Reddy's Laboratories Limited - Dormant Developmental Projects,2015
  • Dr. Reddy's Laboratories Limited - Discontinued Pipeline Products, 2015
  • Dr. Reddy's Laboratories Limited, Subsidiaries

List of Figures

  • Dr. Reddy's Laboratories Limited - Pipeline by Top 10 Indication, 2015
  • Dr. Reddy's Laboratories Limited - Pipeline by Stage of Development, 2015
  • Dr. Reddy's Laboratories Limited - Monotherapy Products in Pipeline, 2015
  • Dr. Reddy's Laboratories Limited - Partnered Products in Pipeline, 2015
  • Dr. Reddy's Laboratories Limited - Pipeline by Top 10 Target, 2015
  • Dr. Reddy's Laboratories Limited - Pipeline by Top 10 Route of Administration, 2015
  • Dr. Reddy's Laboratories Limited - Pipeline by Top 10 Molecule Type, 2015
  • Dr. Reddy's Laboratories Limited - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top